T1CH34.SA Bio-Techne Corporation
- Market cap
- BRL 62.7B
- P/E
- 66.5x
- P/B
- 5.45x
- ROE
- 8.6%
- Dividend yield
- 0.29%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is T1CH34.SA undervalued?
Graham numberThe Graham number of Bio-Techne Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bio-Techne Corporation fundamental analysis
No fundamental analysis for Bio-Techne Corporation yet.
Bio-Techne Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines …
Full company profileBio-Techne Corporation financial statements
Bio-Techne Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 714M | 739M | 931M | 1.11B | 1.14B | 1.16B | 1.22B | 1.22B |
| Gross Profit | 473M | 483M | 633M | 756M | 770M | 773M | 811M | 799M |
| Operating Income | 147M | 149M | 243M | 296M | 348M | 207M | 102M | 273M |
| EBITDA | 212M | 378M | 250M | 414M | 457M | 313M | 217M | 348M |
| Net Income | 96.1M | 229M | 140M | 272M | 285M | 168M | 73.4M | 182M |
| EPS | 0.63 | 1.49 | 0.90 | 1.74 | 1.81 | 1.06 | 0.47 | 1.17 |
| Balance Sheet | ||||||||
| Total Assets | 1.88B | 2.03B | 2.26B | 2.29B | 2.64B | 2.70B | 2.56B | 2.59B |
| Total Liabilities | 719M | 646M | 692M | 594M | 672M | 635M | 639M | 479M |
| Shareholders' Equity | 1.17B | 1.38B | 1.56B | 1.70B | 1.97B | 2.07B | 1.92B | 2.11B |
| Cash & Short-term Investments | 101M | 271M | 232M | 247M | 204M | 153M | 162M | 265M |
| Cash Flow | ||||||||
| Operating Cash Flow | 182M | 205M | 352M | 325M | 254M | 299M | 288M | 292M |
| Capital Expenditure | 25.4M | 51.7M | 44.3M | 44.9M | 38.2M | 62.9M | 31.0M | 28.9M |
| Free Cash Flow | 156M | 153M | 308M | 280M | 216M | 236M | 257M | 263M |
| Ratios | ||||||||
| ROE | 8.2% | 16.6% | 9.0% | 16.0% | 14.5% | 8.1% | 3.8% | 8.6% |
| ROA | 5.1% | 11.3% | 6.2% | 11.9% | 10.8% | 6.2% | 2.9% | 7.0% |
| Net Profit Margin | 13.5% | 31.0% | 15.1% | 24.6% | 25.1% | 14.5% | 6.0% | 15.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bio-Techne Corporation dividends
- Dividend yield
- 0.29%
- Forward dividend
- 0.04 BRL
- Payout ratio
- 27.4%
- Ex-dividend date
- Aug 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 49.9M | 0.32 | 27.4% |
| 2025 | USD 50.4M | 0.33 | 68.7% |
| 2024 | USD 50.4M | 0.32 | 30.0% |
| 2023 | USD 50.3M | 0.32 | 17.6% |
| 2022 | USD 50.2M | 0.32 | 18.4% |
| 2021 | USD 49.6M | 0.32 | 35.3% |
| 2020 | BRL 48.9M | 0.32 | 21.3% |
| 2019 | BRL 48.4M | 0.32 | 50.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Nov 30, 2022.
Who owns Bio-Techne Corporation
Ownership data of Bio-Techne Corporation is not available yet.
Bio-Techne Corporation company profile
- Company name
- Bio-Techne Corporation
- Ticker
- T1CH34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,000
- Fiscal year end
- June
- Address
- 614 McKinley Place N.E., Minneapolis, MN, United States, 55413
- Phone
- 612 379 8854
- Website
- bio-techne.com
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation management
10- Mr. James T. Hippel CPAExecutive VP of Finance & CFO · born 1971
- Mr. Shane V. BohnenSenior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer · born 1975
- Mr. William A. GeistPresident of Protein Sciences Segment · born 1969
- Mr. Steven C. CrousePresident of Diagnostics & Spatial Biology Segment · born 1973
- Dr. Gary J. Latham Ph.D.VP & CTO
- Mr. David Clair C.F.A.Vice President of Investor Relations
- Mr. Martin WirtzSenior Vice President of Strategy & Corporate Development
- Ms. Cheryl BethuneSenior VP & Chief Human Resources Officer
- Mr. Luca CicchettiManaging Director
- Dr. Bernie AndrussSenior Vice President of Bio-Techne Diagnostics Division